Monopar Therapeutics (NASDAQ:MNPR) Stock Gets Price Target Boost from Morgan Stanley

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) had its target price hoisted by stock analysts at Morgan Stanley from $130.00 to $133.00 in a report released on Monday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley‘s price objective would indicate a potential upside of 87.17% from the stock’s previous close.

A number of other analysts also recently commented on the company. HC Wainwright reaffirmed a “buy” rating on shares of Monopar Therapeutics in a research report on Thursday, November 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, October 15th. UBS Group set a $125.00 price objective on Monopar Therapeutics in a research report on Thursday, July 23rd. Barclays restated an “overweight” rating and issued a $145.00 price objective (up from $128.00) on shares of Monopar Therapeutics in a research note on Friday, September 11th. Finally, BTIG Research restated a “buy” rating on shares of Monopar Therapeutics in a research note on Thursday, November 12th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $123.12.

View Our Latest Stock Analysis on MNPR

Monopar Therapeutics Stock Down 1.3%

Shares of MNPR stock opened at $71.06 on Monday. Monopar Therapeutics has a 52-week low of $50.07 and a 52-week high of $124.82. The company has a 50-day simple moving average of $80.82 and a two-hundred day simple moving average of $77.45.

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.72) EPS for the quarter, hitting the consensus estimate of ($0.72). Equities research analysts predict that Monopar Therapeutics will post -2.67 earnings per share for the current year.

Insider Transactions at Monopar Therapeutics

In other Monopar Therapeutics news, CEO Chandler Robinson sold 29,056 shares of the stock in a transaction on Thursday, September 24th. The stock was sold at an average price of $88.00, for a total transaction of $2,556,928.00. Following the completion of the transaction, the chief executive officer directly owned 99,267 shares of the company’s stock, valued at approximately $8,735,496. This represents a 22.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Raymond Anderson sold 3,142 shares of the firm’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $111.77, for a total value of $351,181.34. Following the completion of the sale, the director directly owned 23,751 shares of the company’s stock, valued at $2,654,649.27. This represents a 11.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 51,920 shares of company stock worth $4,527,913 in the last ninety days. Company insiders own 9.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MNPR. Meeder Asset Management Inc. lifted its holdings in Monopar Therapeutics by 18.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 1,651 shares of the company’s stock worth $132,000 after purchasing an additional 262 shares in the last quarter. Sei Investments Co. boosted its stake in Monopar Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after purchasing an additional 656 shares during the period. The Manufacturers Life Insurance Company bought a new position in Monopar Therapeutics in the 1st quarter worth about $250,000. Bank of New York Mellon Corp boosted its stake in Monopar Therapeutics by 21.2% in the 1st quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company’s stock worth $4,307,000 after purchasing an additional 13,761 shares during the period. Finally, ADAR1 Capital Management LLC boosted its stake in Monopar Therapeutics by 13.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after purchasing an additional 30,370 shares during the period. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

(Get Free Report)

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.

Further Reading

Analyst Recommendations for Monopar Therapeutics (NASDAQ:MNPR)

Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.